Drugs
Conditions
News and resources
MIMS Supported Resources
The safety warning was issued following reports of 14 cases of intracranial haemorrhage, including eight fatalities, among 6,840 HIV-infected patients receiving Aptivus in clinical trials.
Although many of the patients had other conditions or were receiving concomitant medication that could have contributed to the intracranial haemorrhage and patients with advanced HIV disease are at an increased risk of suffering such an event, the role of tipranavir cannot be excluded.
Consequently, healthcare professionals are being advised that Aptivus should be used with caution in patients who may be at an increased risk of bleeding from trauma, surgery or other medical conditions, or who are receiving concomitant medication that is known to increase the risk of bleeding.
Further information: Boehringer Ingelheim Ltd, Ellesfield Avenue, Bracknell, Berkshire RG12 8YS. Tel: (01344) 424600.
Although many of the patients had other conditions or were receiving concomitant medication that could have contributed to the intracranial haemorrhage and patients with advanced HIV disease are at an increased risk of suffering such an event, the role of tipranavir cannot be excluded.
Consequently, healthcare professionals are being advised that Aptivus should be used with caution in patients who may be at an increased risk of bleeding from trauma, surgery or other medical conditions, or who are receiving concomitant medication that is known to increase the risk of bleeding.
Further information: Boehringer Ingelheim Ltd, Ellesfield Avenue, Bracknell, Berkshire RG12 8YS. Tel: (01344) 424600.
